Ipsen raids Tesaro for new UK boss as Ewan McDowall heads to Asia

4 September 2018

French drugmaker Ipsen (Euronext: IPN) has named Asad Mohsin Ali (pictured above) as general manager of its UK and Ireland affiliate.

Mr Mohsin Ali is joining from US oncology specialist Tesaro (Nasdaq: TSRO), where he was also the general manager for the UK and Ireland, along with the Nordics, from 2016. Prior to that, he spent 17 years at Swiss pharma giant Novartis (NOVN: VX), working in various global and country roles including the UK, Switzerland and Mexico. His experience covers oncology, hematology and rare diseases.

With Ipsen, he will act as head of site for its global hub in Slough and chair the company’s UK management forum, enabling close alignment with the R&D center in Oxford and manufacturing site in north Wales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK